Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study

BACKGROUND: This study was designed to evaluate the efficacy and safety of fulranumab, a fully human monoclonal antibody directed against nerve growth factor (NGF), for pain relief in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). METHODS: In this multicenter, double-blind study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Russell, Lucille J., Kelly, Kathleen M., Wang, Steven, Thipphawong, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217311/
https://www.ncbi.nlm.nih.gov/pubmed/28056917
http://dx.doi.org/10.1186/s12894-016-0193-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217311/
https://www.ncbi.nlm.nih.gov/pubmed/28056917
http://dx.doi.org/10.1186/s12894-016-0193-z

Ejemplares similares